Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.
Biocon Biologics Ltd: Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Earlier in 2023, over 70 Emerging Markets were integrated in July, the North American business transitioned in September and the European business in November, , Biocon Biologics
Biocon Biologics expands its footprint in Emerging Markets; takes over commercialization of Biosimilars Business from Viatris financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.